Prognostic significance of peritoneal metastasis from colorectal cancer treated with first-line triplet chemotherapy

Table 1 Characteristics of 51 patients with metastatic colorectal cancer, with and without peritoneal metastasis treated with triplet chemotherapy

	Whole group	Peritoneal metastasis N (%)	No peritoneal metastasis N (%)	P value
Age in years	52 (23-74)	52 (23-74)	50 (32-73)	0.97
Gender				0.97
Male	27 (52.9%)	8 (53.3%)	19 (52.8%)
Female	24 (47.1%)	7 (46.7%)	17 (47.1%)
Site of primary				0.03
Left	40 (78.4%)	9 (60%)	31 (86.1%)
Right	11 (21.6%)	6 (40%)	5 (13.9%)
Performance status				0.8
0-1	40 (78.4%)	12 (80%)	28 (77.8%)
2	11 (21.6%)	3 (20%)	8 (22.2%)
Liver metastasis				0.01
Yes	33 (64.7%)	6 (40%)	27 (75%)
No	18 (35.3%)	9 (60%)	9 (25%)
Lung metastasis				0.07
Yes	20 (39.2%)	3 (20%)	17 (47.2%)
No	31 (60.8%)	12 (80%)	19 (52.8%)
KRAS status				0.14
Wild	20 (39.2%)	3 (20%)	17 (47.2%)
Mutant	21 (41.2%)	9 (60%)	12 (33.3%)
Unknown	10 (19.6%)	3 (20%)	7 (19.4%)
Prior surgery to primary				0.3
Yes	29 (55.9%)	10 (66.7%)	19 (52.8%)
No	22 (43.1%)	5 (33.3%)	17 (47.2%)
No of metastatic sites				0.39
1	19 (37.2%)	4 (28.6%)	13 (41.9%)
> 1	32 (62.7%)	10 (71.4%)	18 (58.1%)
Metastasectomy				0.4
Yes	13 (25.5%)	5 (33.3%)	8 (22.2%)
No	38 (74.5%)	10 (66.7%)	28 (77.8%)